Trial
NCT03028740
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tobira Therapeutics, Inc.
Collaborators
—
Condition
Nonalcoholic Steatohepatitis
Intervention
Placebo
Why stopped
This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-10